Skip to content
Screener

Reported July 30, 2026 · Before market open

Revenue$74.3MBeat by $1.0M
EPS-$0.21Miss by $0.03
Revenue estimate$73.2M
EPS estimate-$0.18

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full
Revenue$74.3M+88.0%
Gross profit$59.2M+71.7%
Operating income-$4.0M+93.4%
Net income-$17.6M+76.8%
EPS (diluted)-$0.21+80.0%

Balance sheet

See full
Cash & equivalents$182.5M+22.0%
Total debt$167.1M-18.9%
Total equity-$344.3M+15.2%
Total assets$327.1M+30.7%

Cash flow

See full
Operating cash flow-$1.9M+96.9%
CapEx$44.0K-54.6%
Free cash flow-$2.0M+96.9%

Valuation & ratios

Valuation

as of 06/30/26
See full
Market cap$865.35M+27.0%
Enterprise value$849.99M+15.2%
P/S3.6×-2.4×

Profitability

See full
Gross margin82.9%-4.0pp
Operating margin-17%-8.2pp
Net margin-41.3%-19.1pp
FCF margin-15.4%-7.4pp

Returns & leverage

See full
Current ratio1.9×-0.5×

Segments

By segment

See full
Reportable Segment Aggregation Before Other Operating$74.3M+88.0%

By product

See full
Voquezna Product$74.3M+88.1%

FAQ

When did Phathom Pharmaceuticals, Inc. report Q2 2026 earnings?
Phathom Pharmaceuticals, Inc. (PHAT) reported Q2 2026 earnings on July 30, 2026 before market open.
What were Phathom Pharmaceuticals, Inc.'s Q2 2026 revenue and EPS?
Phathom Pharmaceuticals, Inc. reported revenue of $74.3M and eps of $-0.21 for Q2 2026.
Did Phathom Pharmaceuticals, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $73.2M by $1.0M. EPS missed the consensus estimate of $-0.18 by $0.03.
How did Phathom Pharmaceuticals, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 88.0% from $39.5M a year earlier and eps grew 73.4% from $-0.79.
Where can I find Phathom Pharmaceuticals, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-324865) and the 10-Q periodic report (0001193125-26-324867) directly on SEC EDGAR. The filing index links above go to sec.gov.